Pilot RCT Reports EEG Readouts After ACE Therapy in Schizophrenia

By Tom Whitfield

A pilot randomized controlled trial published ahead of print in Clinical EEG and Neuroscience reports neurophysiological evidence of enhanced cognitive control after Auditory Control Enhancement, or ACE, therapy in adults with schizophrenia-spectrum disorders who experience persistent auditory hallucinations.

The study enrolled adults whose auditory hallucinations continued despite standard care. ACE therapy, the experimental protocol, pairs auditory stimulation with structured cognitive-control exercises. Investigators tracked outcomes with the A-X version of the continuous performance test, or AX-CPT. The paradigm indexes the cognitive-control deficits that prior literature ties to the positive symptoms the intervention targets.

Why the AX-CPT matters here

The test requires subjects to respond to specific cue-probe combinations and to withhold responses to non-target probes. Reaction-time and error patterns under that structure reflect maintenance of goal representations, a function impaired in the same symptom domains ACE therapy aims to address.

Pairing the behavioural read-out with electrophysiological recording gives the trial two streams of evidence. Investigators can read accuracy and latency on the AX-CPT, and they can read the neural signatures that scalp EEG captures around stimulus and response events.

Schizophrenia, the source paper notes, involves positive symptoms such as auditory hallucinations, paranoia, and delusions, and these are commonly linked to deficits in cognitive control. ACE therapy is built to act on those very deficits.

Why publish in an EEG journal

The study appears in Clinical EEG and Neuroscience, a journal whose scope spans quantitative EEG, event-related potentials, and clinical neurophysiology reports. Placing ACE therapy in this venue frames the intervention as an EEG-anchored protocol rather than a behavioural add-on to existing care.

That framing matters for clinical translation. EEG-based readouts can be compared across sites and across trials in a way that pure behavioural scales cannot. Trials that document their electrophysiological pipeline also build reusable reference data for future meta-analyses and post-hoc pooled analyses.

Why a pilot, and why now

Persistent auditory hallucinations sit among the most stubborn positive symptoms in the schizophrenia spectrum. Mechanistically targeted, non-pharmacological protocols occupy a small but growing niche within this clinical space, and ACE therapy adds an auditory-stimulation arm combined with cognitive-control training.

A pilot randomized controlled trial prioritizes feasibility and effect-size estimation rather than formal hypothesis confirmation. The format positions the work as preparation for a larger, registered efficacy study if early signals hold.

Pilot psychiatric RCTs of this kind typically enroll modest sample sizes by design. Their outputs guide power calculations, refine inclusion criteria, and decide whether the larger study is worth running at all.

What an EEG lab does with this

A trial that lands in Clinical EEG and Neuroscience typically commits to electrode-level reporting: site amplitudes, latencies, and time-frequency summaries across the scalp. Reading rooms with cognitive-psychiatry protocols now have an EEG-informed intervention to compare against their own reference data.

For monitoring units and reading rooms, the practical takeaway is direct. Cognitive-control deficits in the schizophrenia spectrum register on EEG, respond to targeted auditory-cognitive training, and now carry an EEG-informed intervention attached in the published record.

What the field will watch

The publication's next test is replication at full trial scale. Whether the pilot matures into a multicenter efficacy study is the question that will determine ACE therapy's place in clinical EEG practice.